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The main role of the plasma membrane Ca2/calmodulin-de-
pendent ATPase (PMCA) is in the removal of Ca2 from the
cytosol. Recently, we and others have suggested a new function for
PMCAas amodulator of signal transductionpathways. This paper
shows the physical interaction between PMCA (isoforms 1 and 4)
and-1 syntrophin and proposes a ternary complex of interaction
between endogenous PMCA, -1 syntrophin, and NOS-1 in car-
diac cells. We have identified that the linker region between the
pleckstrin homology 2 (PH2) and the syntrophin unique (SU)
domains, corresponding to amino acids 399–447 of -1 syntro-
phin, is crucial for interaction with PMCA1 and -4. The PH2 and
the SUdomains alone failed to interactwithPMCA.The function-
ality of the interactionwas demonstrated by investigating the inhi-
bition of neuronal nitric-oxide synthase-1 (NOS-1); PMCA is a
negative regulator ofNOS-1-dependentNOproduction, andover-
expression of -1 syntrophin and PMCA4 resulted in strongly
increased inhibition of NO production. Analysis of the expression
levels of-1 syntrophinprotein in theheart, skeletalmuscle, brain,
uterus, kidney, or liver of PMCA4/mice, did not reveal any dif-
ferences when compared with those found in the same tissues of
wild-type mice. These results suggest that PMCA4 is tethered to
the syntrophin complex as a regulator of NOS-1, but its absence
does not cause collapse of the complex, contrary to what has been
reported forotherproteinswithin thecomplex, suchasdystrophin.
In conclusion, the present data demonstrate for the first time the
localization of PMCA1b and -4b to the syntrophindystrophin
complex in the heart and provide a specific molecular mechanism
of interaction as well as functionality.
Calcium ion (Ca2) regulation is critical for cell function
and survival (1). The mechanisms that increase local calcium
concentration in the heart have been extensively studied,
however, less is known about the calcium extrusion mecha-
nisms. The sarcolemmal calcium pump or plasma membrane
calcium/calmodulin-dependent calcium ATPase (PMCA)3 is
expressed by most cell types, including cardiomyocytes (2).
Four PMCA isoforms have been identified along with multiple
splice variants; all have well defined tissue-specific expression
patterns (2). In non-excitable cells, the primary function of
PMCA is to expel calcium from the cytosol. In excitable cells,
such as cardiomyocytes, the function of PMCA is less clear, as
the sodium/calcium exchanger plays the dominant role in
extrusion of Ca2 across the sarcolemma. As a result, PMCA is
presumed to contribute to the maintenance of low diastolic
Ca2 levels. In addition to their role as Ca2 transporters, our
group and others have identified functional interactions
between PMCAs and cytoplasmic signaling proteins, suggest-
ing a function for PMCAs as modulators of signal transduction
pathways (3–8). The physiological role of PMCA in both cell
signaling and regulation of calcium is emerging through the
development and analysis of transgenic animals with modified
PMCA expression (9–12).
Syntrophin, a member of the dystrophin protein complex
that interacts with the COOH-terminal region of dystrophin, is
involved in organizing functional signaling complexes at the
cytoskeleton-plasma membrane (13–15). The loss of dystro-
phin and subsequent disruption of the dystrophin protein com-
plex from the sarcolemma in Duchenne muscular dystrophy
leads ultimately to degeneration of muscles (16). Disruption of
the dystrophin protein complex has also been implicated in
acquired forms of dilated cardiomyopathy (17) and as a
result of viral myocarditis (18). A cardiomyopathic phenotype
is observed in many patients with Becker muscular dystrophy,
Duchennemuscular dystrophy, as well as othermuscular dystro-
phies, but at the molecular level, the pathogenesis is incompletely
understood (19).
Five isoforms of syntrophin have been described (-1,-1,-2,
-1, and -2), with different tissue distributions and developmen-
tal time courses indicating distinct functions (20–22). Each syn-
trophin isoform comprises four conserved domains, two pleck-
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strin homology domains (PH1 and PH2), a PDZ domain, and a
syntrophin unique (SU) COOH-terminal domain. PH1 and PH2,
socalledas they showhomology toa regionrepeated in theprotein
pleckstrin, have been shown to be involved in the recruitment of
proteins to the sarcolemma (23). The PDZ domain is inserted
within the PH1 domain and has been shown to bind to NOS-1 in
skeletal muscle (24). The SU COOH-terminal domain binds syn-
trophin to dystrophin (25). The fact that there are up to four syn-
trophin binding sites in close proximity within a single dystrophin
complex (26) suggests that syntrophin may bring multiple signal-
ing molecules together to form a large signaling machine. Such
co-localization may improve the efficiency of the signaling com-
plex or increase the specificity of the signals generated by the sig-
naling cascade. In skeletal muscle cells, a muscle-specific isoform
of neuronal nitric-oxide synthase (NOS-1), NOS-1, binds to-1
syntrophin, thereby localizingNOS-1 to the sarcolemmaand the
dystrophin complex (27).Our group has previously demonstrated
thatPMCA4bacts as anegative regulator ofNOS-1 through inter-
actions between the PDZ domain of NOS-1 and the COOH ter-
minus of PMCA (3). We therefore wished to determine whether
PMCA interacted with syntrophin, thereby linking the calcium
pump to signaling from the dystrophin complex.
EXPERIMENTAL PROCEDURES
Cell Culture—HEK293 cells were maintained in Dulbecco’s
modified Eagle’s medium (Invitrogen) supplemented with 10%
fetal calf serum and 1% penicillin/streptomycin.
Plasmids—The expression vectors pCMV-hPMCA4b and
pMM2-hPMCA1b containing the sequence from hPMCA4b
and hPMCA1, respectively, were a gift from Prof. E. Strehler
(Department of Biochemistry and Molecular Biology, Mayo
Clinic, Rochester, MN).
The generation of pBThPMCA4b-(652–840), pFLAG-
hPMCA4b-(652–840), and pFLAG-hPMCA4b-(749–840) has
been described previously (5). The plasmid pcDNA3SYN was
constructed by cloning a NotI and XhoI fragment containing
the -1 syntrophin full-lengthmouse cDNA into pcDNA3 (-1
syntrophin mouse cDNA was a generous gift from Prof. S.
Froehner, Department of Physiology and Biophysics, Univer-
sity of Washington, Seattle, WA). The pFLAG-mSYN con-
structs (numbered according to GenBankTM NM_009228)
were generated by 35 cycles of PCR (the conditions were: dena-
turation at 94 °C for 45 s, annealing at 62 °C for 45 s, and
extension at 72 °C for 1 min) using the oligonucleotides
mSYN81 sense (5-TCTTCCGGAATTCCGTGACGGTGC-
GCAAGGCCG-3), mSYN160 antisense (5-TCTTCGCG-
GATCCTCAAACCTCCAACACAACCTCCTTGCCTG-
3), mSYN292 sense (5-TCTTCCGGAATTCCGGCTGGC-
TGACAGAACAGTTGCCC-3), mSYN399 antisense (5-T-
CTTCGCGAATTCTCAATATGACAGCCATCCACCAA-
CTGTCGGGT-3), mSYN399 sense (5-TCTTCCGGAAT-
TCCATCGGGCTGCTGAAGGCATAC-3), mSYN447 ant-
isense (5-TCTTCGCGGATCCTCACATGGGCTGTCGG-
AGCAGCATGG-3), mSYN447 sense (5-TCTTCCGGAAT-
TCCCCTTCGAGAAACTTCAGATGTCATCAGATG-3),
and mSYN503 antisense (5-TCTTCGCGGATCCTCACTA-
GGCCAAGAGCCCCAAGCGG-3).
Amplified products were cloned into the EcoRI-BamHI sites
of plasmid pFLAG-CMV7.1 (Sigma-Aldrich) and sequenced.
The resulting plasmids pFLAG-mSYN-(81–160), -(292–503),
-(292–447), -(399–503), and -(447–503) encode FLAG-tagged
syntrophin-truncated proteins containing amino acids 81–160,
292–503, 292–447, 399–503, and 447–503, respectively.
Bacterial Two-hybrid Screening—A Human Fetal Heart
cDNA library (Stratagene) was screened using the Bacteri-
oMatchTM two-hybrid system vector kit. The library (2 106
independent cDNA clones) was assayed for resistance to carbe-
nicillin and for-galactosidase expression. Positive cloneswere
sequenced following standard procedures.
Immunoprecipitation in HEK293 Cells and Heart Tissue of
PMCA/Syntrophin/NOS-1—The protocol for immunoprecipi-
tations using transfected HEK293 cells has been described pre-
viously (5). Mouse heart tissue was lysed using radioimmune
precipitation assay buffer (1 phosphate-buffered saline, 1%
Igepal, 0.5% sodium deoxycholate, 0.1% SDS, 20 M phenyl-
methylsulfonyl fluoride, 500 ng/ml leupeptin, 1.0 g/ml apro-
tinin, 500 ng/ml pepstatin). Precleared extracts were incubated
overnight with the corresponding antibody; either 5F10 (an
anti-PMCA monoclonal antibody, Upstate Biotechnology), a
rabbit polyclonal anti-PMCA4b antibody (Swant), a rabbit
polyclonal anti-PMCA1 (Upstate Biotechnology), a rabbit poly-
clonal anti--1 syntrophin (Sigma), a rabbit polyclonal anti-
NOS-1 (Affinity Bioreagents), or a rabbit polyclonal anti-lucif-
erase antibody (Promega). Immunoprecipitated proteins were
recovered by incubationwith proteinA-agarose beads and ana-
lyzed by Western blot.
Transient Transfections—The protocol for transient trans-
fection of HEK293 cells has been described previously for
immunoprecipitation experiments and functionality testing
(5). Cells were co-transfectedwith 1.0g of pCMV-NOS-1 (27)
or the corresponding empty vector (pcDNA3) and the expres-
sion vectors pCMV-hPMCA4b and/or pcDNA3SYN, encoding
human PMCA4b and mouse -1 syntrophin, respectively.
cGMP activity was assessed 24 h after transfection using cGMP
(low pH) colorimetric competitive enzyme-linked immunosor-
bent assay (R & DSystems) to determineNO-dependent cGMP
production as described previously (3).
Pmca4/Mice—We have previously described the genera-
tion of the PMCA4 null mutant mice (10). All animal proce-
dures were performed in accordance with the United Kingdom
Animals (Scientific Procedures) Act of 1986. Tissue was col-
lected from PMCA4 mutant mice and wild-type litter mates at
12 weeks of age. Western blot analysis was undertaken using
anti--1 syntrophin polyclonal antibodies (Sigma) and a sec-
ondary anti-rabbit IgG antibody horseradish peroxidase-conju-
gated (Jackson ImmunoResearch Laboratories). Glyceralde-
hyde-3-phosphate dehydrogenase was used for the protein
loading control, and blots were stripped after initial protein
identification using RestoreTM Western blot stripping buffer
(Pierce) and probed with anti-glyceraldehyde-3-phosphate
dehydrogenase (Advanced Immunochemical) primary anti-
body and then labeled with peroxidase-conjugated goat anti-
mouse IgG (Dako).
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RESULTS
PMCA Interacts with -1 Syntrophin and NOS-1—Previous
work by our group and others has demonstrated the interaction
between theCOOH terminus of PMCAand PDZdomains con-
tained in partner proteins (3, 4, 7, 8, 28). These findings raised
the possibility that -1 syntrophin interacts with PMCA4b via
its PDZ domain. PMCA4b terminates with amino acids ETSV,
which fits the consensus motif E(S/T)XV, essential for binding
to the syntrophin PDZ domain (29). However, two-hybrid
screening of a human fetal heart cDNA library using theCOOH
terminus of PMCA4b as bait failed to identify syntrophin as a
potential interaction partner. Additional two-hybrid screening
was then undertaken using a region of the large catalytic intra-
cellular loop of PMCA4b to identify potential interaction part-
ners. A construct was designed, incorporating amino acids
652–840 (GenBankTM accession number NM_001684) (5).
The screening identified -1 syntrophin as a potential interac-
tion partner of PMCA4. Sequence analysis of the -1 syntro-
phin clone revealed that the sequence encoding for the PDZ
domain (81–164) was absent, and the truncated clone con-
tained amino acids corresponding to the PH2 and SU domains
335–503 (GenBankTM accession number NM_009228).
To confirm the physical interaction between human
PMCA4b and -1 syntrophin, plasmids containing full-
length hPMCA4b (pCMVhPMCA4b) and -1 syntrophin
(pcDNA3SYN) were transfected into HEK293 cells. Protein
extracts were immunoprecipitated with a polyclonal anti--1
syntrophin antibody (Sigma). The presence of PMCA4b among
the precipitated proteins was detected by Western blot with
JA3 (Neomarkers), a mouse monoclonal antibody recognizing
human PMCA4b specifically (Fig. 1A, left panel). Conversely,
protein lysates from transfected HEK293 cells were immuno-
precipitated with a rabbit polyclonal antibody raised against
PMCA4 (Swant) and immunoprecipitated proteins analyzed
byWestern blot using a polyclonal anti--1 syntrophin anti-
body (Sigma). -1 Syntrophin co-precipitated together with
PMCA4, demonstrating the physical interaction between
the two proteins (Fig. 1A, right panel).
The high degree of homology between the PMCA isoforms in
the region encompassing amino acids 652–840 suggested that
other isoforms might also interact with -1 syntrophin. The
functional significance of syntrophin in skeletal and cardiac
muscle prompted us to examine its potential interaction with
PMCA1, the other PMCA isoform expressed in these muscle
types (2). To test this possibility, plasmids pMM2-hPMCA1b
(encoding hPMCA1b) and pcDNA3SYN (encoding mouse -1
syntrophin) were transfected in HEK293 cells. Protein extracts
were immunoprecipitated with an anti-PMCA1 rabbit poly-
clonal antibody (Upstate Biotechnology). Co-precipitated -1
syntrophin was detected by Western blot of the precipitated
samples probed with an anti--1 syntrophin rabbit polyclonal
antibody (Sigma) (Fig. 1B).
Control immunoprecipitations with an irrelevant antibody
(anti-luciferase) did not precipitate any protein, ruling out the
possibility of nonspecific binding of the immunoprecipitating
antibodies to protein A-agarose beads (Fig. 1). These results
demonstrate the physical interaction between ectopically
expressed PMCA4b or PMCA1b and -1 syntrophin and
extend our initial observations from two-hybrid experiments to
mammalian cells.
FIGURE1. Identificationof aphysical interactionbetween-1 syntrophin
and PMCA in mammalian cells. A, HEK293 cells were co-transfected with
expression vectors pCMV-hPMCA4b and pcDNA3SYN encoding human
PMCA4b and mouse -1 syntrophin, respectively. Protein lysates were incu-
batedwith apolyclonal anti--1 syntrophin antibody (Sigma) or a rabbit poly-
clonal antibody specific for PMCA4 (Swant) prior to precipitationwith protein
A-agarose beads.Western blots (WB) of the immunoprecipitated (IP) proteins
were probed with either the JA3 (Neomarkers) monoclonal anti-PMCA4b
antibody (left panel) or anti--1 syntrophin antibody (Sigma) (right panel) to
detect the presence of human PMCA4b or -1 syntrophin, respectively. Co-
precipitation of ectopically expressed human PMCA4b and mouse -1 syn-
trophin suggests thephysical interactionof these twoproteins inmammalian
cells. Immunoprecipitations carried out with an irrelevant antibody (-Luc)
raised against the firefly luciferase ruled out the possibility of nonspecific
binding of immunoprecipitating antibodies to protein A-agarose beads.
B, HEK293 cells were transfected with expression vectors pMM2-hPMCA1b
and pcDNA3SYN encoding human PMCA1b and mouse -1 syntrophin,
respectively. Protein lysates from transfected cells were incubated with an
anti-PMCA1 rabbit polyclonal antibody (Upstate Biotechnology). Western
blot analysis of the precipitated proteins using an anti--1 syntrophin rabbit
polyclonal antibody (Sigma) indicated co-precipitation of PMCA1b and -1
syntrophin. Immunoprecipitations carried out with an irrelevant antibody
(-Luc) raised against the firefly luciferase ruled out the possibility of nonspe-
cific binding of immunoprecipitating antibodies to protein A-agarose beads.
These results demonstrate the interaction in mammalian cells of recombi-
nant -1 syntrophin and isoforms 1b and 4b of the plasma membrane cal-
cium pump.
FIGURE 2. Endogenous PMCA, -1 syntrophin, and NOS-1 physically
interact in cardiac cells.Mouse heart proteins were incubated with a poly-
clonal antibody raised against either -1 syntrophin (-syn) or NOS-1
(-nNOS). Immunoprecipitation (IP) was carried out with protein A-agarose
beads. Western blot (WB) of the immunoprecipitated proteins was probed
with a polyclonal antibody against either PMCA4 (Swant) (upper panel) or
PMCA1 (Upstate Biotechnology) (lower panel). Endogenous -1 syntrophin
and NOS-1 co-precipitated with both PMCA4 and PMCA1, suggesting the
physical interaction of these proteins within a macromolecular complex in
cardiac cells. Control immunoprecipitations carried out with antibodies
raised against PMCA4 (-PMCA4) (upper panel) or PMCA1 (-PMCA1) (lower
panel), respectively, were included as positive controls. Control immunopre-
cipitations performed with an irrelevant polyclonal antibody raised against
the firefly luciferase (-Luc) ruled out nonspecific binding of the immunopre-
cipitating antibodies.
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Endogenous Interaction in the Heart—To confirm the rele-
vance of this interaction in the heart, the physical interaction
between endogenous -1 syntrophin and PMCA was exam-
ined. Previously reported interactions between PMCA and
NOS-1 (3) and -1 syntrophin and NOS-1 (27) suggest these
proteinsmight be part of amacromolecular complex. In view of
the functional significance of -1 syntrophin in the heart and
the expression of PMCA4, PMCA1, andNOS-1 in cardiacmus-
cle (2, 30), we tested this hypothesis in heart tissue. Protein
lysates frommouse heart tissue were immunoprecipitated with
Interaction of PMCA, Syntrophin, and NOS-1
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a polyclonal antibody raised against either -1 syntrophin or
NOS-1 (nNOS). Cardiac PMCA1 and -4 were detected in the
immunoprecipitated proteins by Western blot probed with a
polyclonal antibody against PMCA1 (Upstate Biotechnology)
and a polyclonal antibody against PMCA4 (Swant), respectively
(Fig. 2). These results demonstrate that endogenous -1 syn-
trophin and NOS-1 physically interact with both PMCA4 and
PMCA1 in cardiac cells, suggesting that PMCA, -1 syntro-
phin, andNOS-1 are part of amacromolecular complex in heart
cells.
-1 Syntrophin Interacts with PMCA via a Unique Binding
Domain—Truncated fusion proteins linking the FLAG
epitope to individual, conserved domains of -1 syntrophin
were expressed to identify the binding domain responsible
for the interaction between -1 syntrophin and PMCA. The
bacterial two-hybrid screen identified the COOH-terminal
region of -1 syntrophin, corresponding to amino acids
335–503, as an interaction partner of PMCA4. The COOH
terminus of PMCA4b contains the consensus motif essential
for interaction with syntrophin PDZ domains (29), and ini-
tially it had been presumed that PMCA interacted weakly
with syntrophin via a PDZ ligand-PDZ domain interaction
(2). To determine whether -1 syntrophin could bind simul-
taneously to the large intracellular loop of PMCA4b and the
COOH terminus, FLAG-tagged truncated proteins were
constructed for the PDZ domain (pFLAG-mSYN-(81–160)),
PH2 domain (pFLAG-mSYN-(292–399)), a region spanning the
PH2 and SU domains (pFLAG-mSYN-(292–503)), and the SU
(pFLAG-mSYN-(447–503)) domain of -1 syntrophin (Fig.
3A). These plasmids were transfected in HEK293 cells and
assayed by immunoprecipitation for their abilities to interact
with ectopically expressed human PMCA4b. The region span-
ning the PH2 and SU domains (pFLAG-mSYN-(292–503)) co-
precipitatedwith PMCA4b (Fig. 3B, left upper panel). However,
no precipitation was observed with the PDZ, PH2, or SU
domains (Fig. 3B, left upper panel). This result indicated that
either both the PH2 and SU domains were important for inter-
action with PMCA4b to take place or that a linker region
(amino acids 399–447) between the two domains was critical.
To resolve this, new constructs encoding FLAG-tagged fusion
proteins were generated containing either the PH2 domain
with the linker region (pFLAG-mSYN-(292–447)) or the SU
domainwith the linker region (pFLAG-mSYN-(399–503)). Co-
precipitation experiments confirmed that both plasmids inter-
acted with PMCA4b (Fig. 3B, right upper panel), thereby estab-
lishing that amino acids 399–447 are critical for-1 syntrophin
to interact with PMCA4b. Western blot analysis of the immu-
noprecipitated proteins probed with a polyclonal antibody spe-
cific for PMCA4 (Swant) showed comparable levels of PMCA4
immunoprecipitation in all cases, thus ruling out the possibility
of poor immunoprecipitation as the reason for the lack of inter-
action (Fig. 3B, lower panels).
Having previously demonstrated the interaction of -1 syn-
trophin with both the PMCA4 and -1 isoforms, we wished to
determine whether the same interaction domain of -1 syntro-
FIGURE 3. -1 Syntrophin interacts with both PMCA4b and -1b via a unique binding domain. A, schematic diagram of the -1 syntrophin domains
used to generate -1 syntrophin truncated FLAG-tagged fusion proteins. The numbers correspond to amino acids, according to GenBankTM accession
number Q61234. B, amino acids 399–447 of -1 syntrophin are critical for its interaction with PMCA4b. HEK293 cells were co-transfected with an
expression vector encoding PMCA4b (pCMV-hPMCA4b) and the corresponding construct expressing FLAG-syntrophin truncated proteins as indicated
above the lanes. Proteins were immunoprecipitated with the anti-PMCA 5F10 monoclonal antibody and the presence of co-immunoprecipitated
FLAG-syntrophin proteins detected byWestern blot (WB) using the M2 anti-FLAG peroxidase-conjugatedmonoclonal antibody. This experiment shows
that the peptide corresponding to the PH2 and SU domains (pFLAG-mSYN-(292–503)) interacts with hPMCAb (left upper panel). The truncated proteins
corresponding to the PDZ domain (pFLAG-mSYN-(81–160)), PH2 domain (pFLAG-mSYN-(292–399)), and SU domain (pFLAG-mSYN-(447–503)) do not
interact with full-length hPMCA4b (left upper panel). The truncated proteins corresponding to the PH2 domain, including the linker region (pFLAG-
mSYN-(292–447)), and the SU domain, including the linker region (pFLAG-mSYN-(399–503)), interacted with full-length PMCA4b (right upper panel).
These results demonstrate that the linker region (amino acids 399–447) is critical for the interaction between -1 syntrophin and PMCA4b. Levels of
immunoprecipitated PMCA4b in the different transfection experiments were confirmed to be comparable by Western blot using a polyclonal antibody
specific for PMCA4 (Swant) (lower panels), thus ruling out the possibility of poor immunoprecipitation as the reason for lack of interaction. Control
immunoprecipitations using an antibody against firefly luciferase ( -Luc) were carried out to rule out nonspecific binding of antibodies to protein
A-agarose beads. C, the domain of -1 syntrophin involved in the interaction with PMCA4b also mediates the interaction with PMCA1b. HEK293 cells
were co-transfected with pMM2-hPMCA1b, an expression vector encoding PMCA1b, and the plasmids encoding the FLAG-syntrophin truncated fusion
proteins described in B. As reported for PMCA4b, immunoprecipitation experiments demonstrated that domain 399–447 of -1 syntrophin is also
critical for the interactionwith PMCA1b (upper panels). Levels of immunoprecipitated PMCA1b in the different transfection experiments were confirmed
to be comparable by Western blot using a polyclonal antibody specific for PMCA1 (Upstate Biotechnology) (lower panels), thus ruling out the possibility
of poor immunoprecipitation as the reason for lack of interaction. Control immunoprecipitations using an antibody against firefly luciferase ( -Luc)
were carried out to rule out nonspecific binding of antibodies to protein A-agarose beads.
FIGURE 4. Co-expression of -1 syntrophin and hPMCA4b inhibits NO
production.HEK293 cells were co-transfectedwith either NOS-1,-1 syntro-
phin, PMCA4b, or pcDNA3 empty vector or with a combination of vectors.
Ectopic expression of NOS-1 enhanced cGMP production in HEK293 cells.
Co-expression of mouse -1 syntrophin or human PMCA4b, together with
NOS-1, reduced the NOS-1-dependent cGMP production by 38 and 58%,
respectively. When both -1 syntrophin and PMCA4b were co-expressed in
the presence of NOS-1, 84% inhibition in the production of cGMP was
observed. These results suggest that the interaction of PMCA4b and -1 syn-
trophin synergistically inhibit NOS-1-mediated NO production. The asterisk
denotes statistically significant (p 0.01, according to Student’s t test) inhi-
bition in NO production as observed in cGMP production. Means S.E. of
three independent experiments are shown. Data are expressed as fold induc-
tion over the value obtained in cells transfected with the corresponding
empty vector.
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phin was responsible for interaction with PMCA4 and -1.
HEK293 cells were co-transfected with an expression plasmid
encoding PMCA1b (pMM2-hPMCA1b) and the FLAG-tagged
truncated versions of-1 syntrophin described above. Identical
results to that observed for PMCA4were obtainedwithPMCA1
(Fig. 3C), demonstrating that interactionwith either PMCA1or
-4 maps to the same domain (399–447) of -1 syntrophin.
-1 Syntrophin Modulates NOS-1 Activity—Our group has
recently shown that PMCA4b negatively regulates the activity of
NOS-1 (3). The functional consequences of the interaction
between -1 syntrophin and PMCA may thus involve the syner-
gistic action of -1 syntrophin and PMCA in regulating NOS-1
activity. It is known that -1 syntro-
phin interacts with NOS-1 (27) and
that PMCA4b and NOS-1 interact;
we therefore wished to determine
whether the formation of the com-
plex PMCA4b -1 syntrophinN-
OS-1 negatively regulates NO produ-
ction. Transient transfection of -1
syntrophin in the presence of NOS-1
led to a 38% reduction in NOS-1 act-
ivity (Fig. 4). Co-expression of both
proteins produced an 84% (p 0.05)
reduction over and above that
observed by the expression of PM-
CA4b alone (58%) (Fig. 4). The ex-
pressionof-1 syntrophin,PMCA4b,
or pcDNA3 empty vector control in
the absence of NOS-1 did not alter
cGMP production (data not shown).
These results suggest that the intera-
ction of PMCA4b and syntrophin
synergistically inhibit NOS-1-medi-
ated NO production, because
maximum inhibition was observed in
cells expressing both proteins.
-1 Syntrophin Protein Levels Are
Unaffected in PMCA4/ Mice—
We have generated PMCA4 null
mutant mice (10) to determine the
role of PMCA4 in the regulation of
cardiac function.Western blot analy-
sis demonstrated that -1 syntrophin
protein expression was not altered in
the heart, skeletal muscle, brain,
uterus, kidney, or liver of PMCA4/
mice when compared with the
expression of the protein in the same
tissues of wild-type littermates at
three months of age (p 0.001) (Fig.
5 and data not shown). The Western
blots were normalized by comparing
the levels of glyceraldehyde 3-phos-
phate dehydrogenase protein expres-
sion. These results suggest that
PMCA4 is tethered to the syntrophin
complex as a regulator of NOS-I, but
its absence does not cause collapse of the complex, contrary to
what has been reported for other proteins within the complex,
such as dystrophin.
DISCUSSION
Our initial hypothesis was that syntrophin binds to PMCA4b
via the PDZbindingmotif and, through these interactions, links
PMCA signaling to the dystrophin complex. We have previ-
ously shown that PMCA4b and NOS-1 interact via PDZ bind-
ing and that PMCA inhibits NOS-1 activity (3). -1 Syntrophin
contains a PDZ domain that could potentially bind to the ETSV
consensus sequence at the COOH terminus of PMCA4b. How-
FIGURE 5.-1 Syntrophin protein levels are unaffected in PMCA4/mice. Expression levels of-1 syntro-
phin in hearts or skeletal muscle of 3-month-old wild-type or PMCA4 null mice were analyzed byWestern blot
(WB) using a polyclonal anti--1 syntrophin antibody (Sigma). Levels of -1 syntrophin were compared with
those of the housekeeping protein glyceraldehyde-3-phosphate dehydrogenase (GAPDH) detected with an
anti-GAPDH antibody (Advanced Immunochemical). Data from the densitometry analysis of Western blots
from different animals (n 3) showed no alterations in the levels of -1 syntrophin between wild-type and
PMCA4/ animals.
FIGURE 6. Diagrammatic representation of the interaction between PMCA, -1 syntrophin, and NOS-1.
Thediagramhighlights the interaction between PMCAvia syntrophin andNOS-1 to dystrophin. The expanded
diagramprovides amoredetailed illustrationof thebindingof PMCAvia the intracellular loop locatedbetween
transmembrane domains 4 and 5 to syntrophin and via the COOH terminus to the PDZ domain of NOS-1.
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ever, in this paper, we have shown that the PDZ domain of -1
syntrophin does not interact directly with full-length PMCA4b.
We have established that -1 syntrophin interacts with the dis-
tal region of the large intracellular loop of PMCA4. Our group
has previously reported a functional interaction between this
domain of PMCA4 and the Ras association factor RASSF1 (5).
The interaction of another protein with the same region of
PMCA highlights the importance of the large cytoplasmic loop
of PMCA for associations with partner proteins. We are cur-
rently investigating the effect of this interaction on the calcium-
pumping function of PMCA.
We have also determined that the linker region between the
PH2 and SU domains (corresponding to amino acids 399–447)
of -1 syntrophin is crucial for the interaction to take place.
This is similar to themechanism that has been reported for -1
syntrophin binding to utrophin, where individual PH2 or SU
domains fail to bind (31) and interaction only takes place in the
presence of both domains. We propose a model for a ternary
interaction between PMCA, -1 syntrophin, and NOS-1 (Fig.
6), where PMCA4b is linked to NOS-1 through interactions
between the COOH-terminal tail of PMCA and the PDZ
domain of NOS-1 and -1 syntrophin is tethered to the com-
plex through interactions between the linker region between
the PH2 and SU domains and the large intracellular loop
between transmembrane regions four and five of PMCA4.
There is a growing body of evidence suggesting that PMCA
acts as a modulator of signal transduction pathways (3–8). In
this work, we have established that PMCA and -1 syntrophin
act synergistically to negatively regulate NOS-1 activity, which
has significant implications for the functional role of this inter-
action on nitric oxide-regulated signaling pathways. The
importance of NOS-1 signaling in the heart is well established.
NOS-1 ablation enhances basal contractility (33, 34), andNOS-
1-derived NO increases as a consequence of experimental and
pathological human heart failure (35). It has recently been
shown thatNOS-1 expression is up-regulated in the final stages
of late phase ischemic preconditioning (36), suggesting it may
be important in protecting the heart against myocardial infarc-
tion. The role of the interactions between PMCA, -1 syntro-
phin, and NOS-1 on NOS-1 regulation in cardiac cells requires
further investigation.
We have not detected modifications in the levels of -1 syn-
trophin expressed in the hearts of transgenic PMCA4 knock-
out mice. We show that PMCA1, the other isoform of PMCA
present in cardiac muscle, is also able to bind to -1 syntrophin
in cardiac cells. Therefore, it is likely that the lack of PMCA4
expression can be compensated for by the presence of PMCA1
in the PMCA4/ mice. Loss of PMCA1 in null mutant mice
results in embryonic lethality (11), making difficult the genera-
tion of PMCA1/4 double knock-out mice required to study the
physiological consequences of the disruption of the PMCA-
syntrophin interaction.
Our molecular model of a PMCA-1 syntrophinNOS-1
complex also brings PMCA into close contact with the dystro-
phin protein complex, where it could regulate signaling either
through direct interactions or by alterations in Ca2 and/or
nitric oxide signaling. Dystrophin has been shown to co-local-
ize with the cardiac L-type Ca2 channel and inactivate channel
activity (32). This inactivation was reduced in cardiacmyocytes
from mice lacking dystrophin (mdx mice) (32). One theory is
that cardiac tissue becomes more susceptible to damage from
Ca2 loading, and cytoskeletal disruption appears to alter Ca2
channel kinetics, a potential mechanism for cardiac dysfunc-
tion observed in Duchenne and Becker muscular dystrophies
(32). We speculate that an analogous system may exist for the
regulation of PMCAactivity by dystrophin via interactionswith
-1 syntrophin.
In conclusion, the present data demonstrate for the first time
the localization of PMCA1b and -4b to the syntrophindystrophin
complex in the heart and provide a specificmolecularmechanism
of interaction as well as functionality.We are currently investigat-
inghowthis interactionregulatesnitric-oxide synthaseactivityat a
molecular level. It will be interesting to address these observations
in other tissues that contain the complex, such as skeletal, smooth
muscle, and brain tissues.
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